| Literature DB >> 33999309 |
Fang Xiong1,2,3, Kunjie Zhu4, Su Deng1, Hongbin Huang1, Liting Yang2, Zhaojian Gong5, Lei Shi5, Yi He4, Yanyan Tang4, Qianjin Liao4, Jianjun Yu4, Xiaoling Li3, Yong Li6, Guiyuan Li3, Zhaoyang Zeng3, Wei Xiong3, Shanshan Zhang7, Can Guo8.
Abstract
Long non-coding RNAs (lncRNAs) have become a hotspot in biomedical research. This interest reflects their extensive involvement in the regulation of the expression of other genes, and their influence on the occurrence and development of a variety of human diseases. Actin filament associated protein 1-Antisense RNA 1(AFAP1-AS1) is a recently discovered oncogenic lncRNA. It is highly expressed in a variety of solid tumors, and regulates the expression of downstream genes and signaling pathways through adsorption and competing microRNAs, or by the direct binding to other proteins. Ultimately, AFAP1-AS1 promotes proliferation, chemotherapy resistance, and resistance to apoptosis, maintains stemness, and enhances invasion and migration of tumor cells. This paper summarizes the research concerning AFAP1-AS1 in malignant tumors, including the clinical application prospects of AFAP1-AS1 as a potential molecular marker and therapeutic target of malignant tumors. We also discuss the limitations in the knowledge of AFAP1-AS1 and directions of further research. AFAP1-AS1 is expected to provide an example for studies of other lncRNA molecules.Entities:
Keywords: AFAP1-AS1; PD-1; anti-cancer drug; immunotherapy; metastasis; proliferation
Mesh：
Substances：
Year: 2021 PMID： 33999309 DOI： 10.1007/s11427-020-1874-6
Source DB: PubMed Journal: Sci China Life Sci ISSN： 1674-7305 Impact factor: 6.038